Business Wire

Quintiles Introduces Continuous Glucose Monitoring Services to Improve Diabetes Outcomes

Del

Quintiles today announced the launch of its new Continuous Glucose Monitoring (CGM) service offering. This new solution combines innovative, wearable technology with Quintiles’ deep therapeutic and analytical expertise to help enhance the efficiency and quality of diabetes-focused clinical trials.

When used in clinical research, the new CGM offering will provide investigators with access to a myriad of customized data analytics and performance reports through its award-winning Quintiles Infosario® technology platform. These optimized glycemic data sets can be analyzed more efficiently to uncover trends such as non-compliance and potential safety triggers faster than traditional diabetes monitoring models. In addition, Quintiles experts from the company’s Diabetes Center of Excellence will provide dedicated support for the offering – combining data and therapeutic expertise to drive smarter protocol design and enhance patient safety and compliance.

“According to the International Diabetes Federation (IDF), every six seconds, a person dies from diabetes-related causes and almost half of those deaths are people under the age of 60,” said Margaret Keegan, president of Data Sciences, Safety and Regulatory Services at Quintiles. “With diabetes diagnoses on the rise, the need for innovative and accessible treatments also increases. CGM can provide a variety of in-depth measures from diabetes patients – information that can be used to enhance the way patients are treated for diabetes and why this new offering is so critical.”

Through the offering, continuous glucose measurements will be captured by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day. In the clinical trial setting, this comprehensive and timely glucose visibility has the potential to improve patient safety, accelerate clinical development and provide a basis for differentiated claims.

“We are excited to bring this new CGM offering to the market as a complement to Quintiles’ technology integration strategy,” said Sam Osman, head of Cardiac Safety Services at Quintiles. “We believe this new technology solution incorporating biosensors and wearables, which can be used across all drug development phases, will improve the way the industry tracks and improves diabetes care for patients worldwide.”

To learn more about Quintiles Continuous Glucose Monitoring, visit quintiles.com/cgm.

About Quintiles

Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

Contact information

Quintiles
Media Relations
Phil Bridges
Office: + 1-919-998-1653
Mobile: + 1-919-457-6347
phil.bridges@quintiles.com
or
Investor Relations
Todd Kasper
+1-919-998-2590
InvestorRelations@quintiles.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Tempo Grows Revenue by 38% in 2017 to $17.9 Million19.2.2018 11:14Pressemelding

Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017. “2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.” Highlights for 2017 include: Revenue grew 38% year-over-year to US$17.9 million Almost 2,000 new customers were acquired Launched our new cloud infrastructure Expanded product footprint beyond the Atlassian environment with Tempo for Slack North American operations continued to grow More than 120 partners worldwide Celebrated our 10-year an

Morrow Sodali Announces Appointment of David Shammai as Corporate Governance Director - Cross Border19.2.2018 10:05Pressemelding

Morrow Sodali today announced that David Shammai has joined the firm as Corporate Governance Director - Cross Border. David joins from APG Asset Management, the Dutch pension fund manager, where in his role as senior corporate governance specialist he was involved in voting, policy, and engagement. Based in the London office, David will focus on the firm’s growing corporate governance activities across its European offices. Together with Morrow Sodali’s expanding team of corporate governance professionals, David will work to further develop the firm’s governance services – ranging from benchmarking and assessments of governance practice to board advisory on engagement with investors. “At Morrow Sodali we recognise that today many of our clients face growing needs for an in-depth and meaningful dialogue with their investors on a broadening range of topics. Having David onboard - from one of the world’s largest fiduciary asset managers - demonstrates our reinforced commitment to helping

MagicStay Expands Its Signature Series with onefinestay19.2.2018 09:09Pressemelding

MagicStay.com , the apartment rental platform for business travelers, is expanding its upscale offering by distributing onefinestay apartments. MagicStay's Signature® range features a selection of upscale and design apartments, managed by professional agencies that pay particular attention to the quality of hospitality and services offered. onefinestay, the world’s leading luxury private rental brand, is positioned in the 4 and 5 star range that can appeal to a business clientele. onefinestay is renowned in the hospitality industry for its high-touch service, which is always curated to each guest and stay. The company, which joined the AccorHotels group in 2016 offers a peace of mind promise which meets MagicStay’s quality and safety criteria. More than 1,000 homes from onefinestay's portfolio in popular business destinations such as London, Paris, New York or Los Angeles complete the MagicStay Signature® range, offering distinctive and authentic accommodation in city centres. Business

GSMA Announces Winners of Inaugural Mobile World Scholar Challenge19.2.2018 09:00Pressemelding

The GSMA today announced the winners of its inaugural Mobile World Scholar Challenge. New for Mobile World Congress 2018, the Mobile World Scholar Challenge is a video-based competition designed to discover and highlight ground-breaking new technologies developed at universities around the globe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005023/en/ GSMA Submitted Photo “Embracing new ideas is the key to innovation and growth, be it an economy, an industry, a company, charity or individual,” said John Hoffman, CEO, GSMA Ltd. “At Mobile World Congress, we are constantly looking to showcase cutting-edge ideas poised to impact the mobile world, and the winners of this first Mobile World Scholar Challenge certainly represent this. Our congratulations to all of the winners, as well as everyone who submitted their innovations for consideration.” Challenge participants submitted short-form videos that promote the science b

Reply 2018 Code Challenge: Join Us19.2.2018 09:00Pressemelding

On 15th March 2018 Reply will launch the first Reply Code Challenge, focused on team programming and open to students and professional coders. All the participant teams who have registered on challenges.reply.com will face the challenge of solving a logical math problem through coding. The idea for code challenges came from the “Reply Code Master Team”, a group of Reply developers passionate about coding competitions and design. After a first internal round involving Replyers, Reply is now opening the challenge up to the world. It’s all about learning together and the fun of competition. Reply believes and invests in talent scouting and lifelong learning. The Reply Code Challenge initiative is part of Reply’s ongoing efforts to promote coding to young people (i.e.: The Code for Kids program that involved more than 15,000 girls and boys among 6-18 years in Europe in the last 24 months) to businesses and geeks. Sign up on challenges.reply.com from 15th February, create a team, and connec

New Data Demonstrates Long-Term Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis Treated with Janssen’s TREMFYA® (guselkumab)19.2.2018 08:00Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA® (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.1 Findings from the study also demonstrated that a vast majority of patients originally randomised to guselkumab, but withdrawn from treatment at week 28, regained a PASI 90 response within six months of initiating guselkumab retreatment.1 These long-term findings from the Phase III VOYAGE 2 study were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, during a late-breaking abstract session at 1:00 PM PST (22:00 CET) on Saturday 17 February. “The longer-term data from VOYAGE 2 shows promising results for guselkumab as both a continuous, long-term treatment for mod